CG Oncology (NASDAQ:CGON) Releases Earnings Results, Misses Expectations By $0.24 EPS

CG Oncology (NASDAQ:CGON) issued its quarterly earnings data on Friday. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.24), FiscalAI reports. The firm had revenue of $1.16 million during the quarter, compared to analyst estimates of $0.36 million. CG Oncology had a negative return on equity of 26.58% and a negative net margin of 3,602.68%.

CG Oncology Stock Performance

Shares of NASDAQ:CGON traded up $0.25 on Friday, hitting $75.10. 610,786 shares of the company were exchanged, compared to its average volume of 925,978. The company’s 50 day moving average price is $67.12 and its two-hundred day moving average price is $63.95. The firm has a market capitalization of $6.62 billion, a price-to-earnings ratio of -27.92 and a beta of 0.23. CG Oncology has a one year low of $23.65 and a one year high of $77.00.

CG Oncology News Roundup

Here are the key news stories impacting CG Oncology this week:

• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $82 to $85 and assigned an “overweight” rating, implying approximately 13.2% upside. Benzinga
• Positive Sentiment: Truist Financial also raised its target from $82 to $85 and upgraded its view to “buy,” citing a more constructive outlook for CG Oncology. The Fly
• Positive Sentiment: HC Wainwright maintained a “buy” rating and a $100 target. The firm modestly increased its long-term FY2030 EPS forecast to $6.88 from $6.77, reinforcing expectations for significant future earnings growth as the company advances its pipeline. MarketBeat
• Positive Sentiment: CG Oncology reported second-quarter revenue of $1.16 million, substantially above the $0.36 million consensus estimate, while also highlighting pipeline and business progress. CG Oncology Second-Quarter Results
• Neutral Sentiment: Royal Bank of Canada lowered its target from $81 to $79 but retained an “outperform” rating. The reduced target still represents roughly 5.2% potential upside and may reflect valuation calibration rather than a fundamental downgrade. Ticker Report
• Negative Sentiment: CG Oncology reported a quarterly loss of $0.90 per share, wider than the $0.66 consensus loss and the $0.54 loss recorded a year earlier. The earnings shortfall could limit gains despite strong analyst targets. Zacks Q2 Earnings Report
• Negative Sentiment: HC Wainwright reduced its FY2029 EPS estimate from $2.43 to $2.34, signaling some moderation in its intermediate-term earnings outlook, although its buy rating and $100 target remain unchanged.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Royal Bank Of Canada dropped their target price on shares of CG Oncology from $81.00 to $79.00 and set an “outperform” rating on the stock in a report on Friday. Truist Financial lifted their price objective on CG Oncology from $82.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday. JPMorgan Chase & Co. boosted their price objective on CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of CG Oncology in a research note on Wednesday, July 29th. Finally, Piper Sandler raised their target price on CG Oncology from $82.00 to $85.00 and gave the company an “overweight” rating in a report on Friday. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $83.18.

Insider Activity at CG Oncology

In other CG Oncology news, Director James Mulay sold 24,165 shares of the stock in a transaction on Friday, July 10th. The stock was sold at an average price of $75.16, for a total transaction of $1,816,241.40. Following the completion of the transaction, the director directly owned 24,165 shares in the company, valued at $1,816,241.40. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Brian Guan-Chyun Liu bought 371,085 shares of CG Oncology stock in a transaction dated Thursday, June 25th. The stock was purchased at an average price of $66.87 per share, for a total transaction of $24,814,453.95. Following the purchase, the director directly owned 1,886,236 shares in the company, valued at $126,132,601.32. This represents a 24.49% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold 37,129 shares of company stock worth $2,663,817 over the last three months. Company insiders own 4.80% of the company’s stock.

Hedge Funds Weigh In On CG Oncology

Several institutional investors have recently bought and sold shares of CGON. LPL Financial LLC increased its holdings in shares of CG Oncology by 9.8% in the fourth quarter. LPL Financial LLC now owns 6,201 shares of the company’s stock worth $257,000 after acquiring an additional 551 shares in the last quarter. Swiss National Bank lifted its stake in CG Oncology by 1.5% in the third quarter. Swiss National Bank now owns 81,300 shares of the company’s stock valued at $3,275,000 after buying an additional 1,200 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of CG Oncology by 5.3% in the second quarter. Invesco Ltd. now owns 29,231 shares of the company’s stock valued at $760,000 after buying an additional 1,477 shares during the period. Federated Hermes Inc. raised its holdings in shares of CG Oncology by 20.0% in the second quarter. Federated Hermes Inc. now owns 10,200 shares of the company’s stock valued at $265,000 after purchasing an additional 1,700 shares during the last quarter. Finally, Virtus Investment Advisers LLC lifted its position in CG Oncology by 51.3% during the 4th quarter. Virtus Investment Advisers LLC now owns 6,497 shares of the company’s stock worth $270,000 after buying an additional 2,203 shares in the last quarter. Institutional investors own 26.56% of the company’s stock.

About CG Oncology

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.